Methods and kits for assessing the propensity of developing urolithiasis, kidney disease, or bladder disease in pets; and compositions to treat such conditions are described herein.

The treatment of diabetes mellitus with excellent hypoglycemic effect that suppresses lactic acidosis without substantially increasing the blood lactate concentration. A composition for treating diabetes mellitus with hypoglycemic effect that suppresses lactic acidosis without substantially increasing the blood lactate concentration, and the composition has branched-chain amino acids and salts of biguanide derivatives and derivatives of biguanide derivatives or branched-chain amino acids as the active components. The composition will be more effective when leucine, isoleucine, or valine is included as branched-chain amino acids, and metformin as the biguanide derivative.

A method of treating an asthmatic subject is provided. The method includes determining serum level of serum amyloid A (SAA) in the subject; comparing the serum level with a pre-determined threshold; and administering to the subject a therapeutically effective amount of a COX-2 inhibitor if the serum level is greater than or equal to the threshold.

The present invention is to provide methods and devices that monitoring health and diagnosing a disease by directly measuring the biomarkers inside a cell (intra-cellular detection) rapidly and easily.

The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that may introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.

Methods of diagnosing Crohn’s disease and ulcerative colitis in subjects is provided based on the determination of metabolites in urine samples, such as serine, hypoxanthine, kynurenine, threonine, dimethylglycine, tryptophan, indoxylsul-fate, phenylacetylglutamine, sialic acid, 5-hydroxy-6-indolyl-o-sulfate, 5-(Δ-carboxybutyl) homocysteine, and/or an anion having m/ z:RMT:polarity of 345.1553:0.770:n, or determination of metabolites in stool samples, such as ketodeoxycholic acid, cholic acid, choline, tryptophan, trimethyllysine, serine, butyric acid, lactic acid, hypoxanthine and/or guanine.

The present invention relates to diagnostic methods to assess the presence of quorum sensing molecules (QSM), preferably peptides (QSPs), that influence muscle wasting in humans. The present invention furthermore relates to the use of the knowledge obtained by the diagnostic method in order to influence muscle wasting diseases in animals and human, by for example providing bacteria that produce beneficial QSMs or non-harmful QSMs, providing antagonists for harmful QSMs and the like.

The purpose of the present invention is to provide: a method for testing the aggravation risk for a person infected with the COVID-19 virus, the method allowing the use of urine as a test sample; a test kit for the method; and a companion diagnostic drug and an aggravation risk marker thereof. The present invention is a method that includes a step for determining the amount of liver fatty acid binding protein in urine sampled from a subject, and that tests the aggravation risk of SARS-CoV-2 infectious disease (COVID-19) on the basis of the quantitative determination result.

An inflammatory marker is calculated using a nonlinear function including, as variables, a parameter associated with an erythrocyte aggregation and another parameter associated with an erythrocyte density. The parameter associated with the erythrocyte aggregation is calculated based on a syllectogram measured from a blood specimen. The parameter associated with the erythrocyte density is measured from the blood specimen.

The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the β.sub.1 adrenergic receptor gene.